Drug · Small Molecule

Carboplatin

CI-DRUG-00000139Explore in graph →NCIt C1282 CHEMBL1351 CIViC Approved

Regulatory

Approvals (13)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory11 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02320371) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 11, 2015	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION (DIN 02366053) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Jul 28, 2020	Jun 10, 2013	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02126680) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	674	340	543	2,363	13	CA, US	Dec 31, 1994	1988-03
Malignant Ovarian Neoplasm	Approved	Phase 4	52	26	61	282	2	US	Aug 8, 2025	1989-04
Malignant Lung Neoplasm	Phase4	Phase 4	243	118	220	824	0	—	—	1994-12
Malignant Breast Neoplasm	Phase4	Phase 4	88	40	47	267	0

Curated evidence

Clinical evidence (38)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–38 of 38 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CCND1 Amplification1
Carboplatin + Paclitaxel

Clinical trials

Trials with this intervention (2,387)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 151–200 of 2,387 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04092283	Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer	active not recruiting	Phase 3	660	National Cancer Institute (NCI)NIH	2	Sep 8, 2026	clinicaltrials
NCT05789082	A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Molecule

Record

Kind: Small Molecule
Mechanism: DNA inhibitor
UNII: BG3F62OND5
Aliases: 1,1-cyclobutanedicarboxylic Acid Platinum Complex, Blastocarb, Carboplat, Carboplatin, Carboplatine, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II), Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum, Cis-diammine(cyclobutanedicarboxylato)platinum II, Displata, Ercar, JM-8, JM8, KYXATA, Nealorin, Novoplatinum, NSC-201345, NSC-241240, Paraplat, Paraplatin, Paraplatin AQ, PARAPLATIN-AQ, Paraplatine, Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2) … (+3)

Data updated 2 hours agoSource updated unknown

Identifiers

Codes (23)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01XA02	CARBOPLATIN
DIN (Health Canada)	00680060

High2
Carboplatin + Dostarlimab + PaclitaxelCombination	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	5	submitted	EID12341 A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC) PMID 36972026 · Mirza et al., 2023 · Open in CIViC	civic
〃	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	5	submitted	EID12343 A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC) PMID 38866180 · Powell et al., 2024 · Open in CIViC	civic

PTEN Loss2
Buparlisib + Carboplatin + PaclitaxelCombination	Malignant NeoplasmALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID714 All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers. PMID 25672916 · Hyman et al., 2015 · Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID5957 In one arm of this phase 1b study, 7 patients with PTEN deficient tumors were treated with continuous buparlisib (100 mg/daily) orally plus standard dose carboplatin AUC 5 and paclitaxel 175 mg/m2. No… (full text at CIViC) PMID 28281183 · Smyth et al., 2017 · Open in CIViC	civic

NF1 G629R + NF1 Splice Site (c.205-1G>C)2
Carboplatin + Selumetinib + Trametinib + VincristineSubstitutes	Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID12271 This study reported 47 neurofibromatosis type 1 (NF1) patients with biallelic inactivation of NF1 genes were detected in all glial tumors. Targeted capture-based next-generation sequencing (479 cancer… (full text at CIViC) PMID 35945463 · Lucas et al., 2022 · Open in CIViC	civic
〃	Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	2	rejected	EID12359 This study reported 47 neurofibromatosis type 1 (NF1) patients with biallelic inactivation of NF1 genes were detected in all glial tumors. Targeted capture-based next-generation sequencing (479 cancer… (full text at CIViC) PMID 35945463 · Lucas et al., 2022 · Open in CIViC	civic